Safety Study of an Immune Response Modifier in Patients With Refractory Solid Organ Tumors

NCT00095160 | Completed Phase 1

• 2 other identifiers: 2003LS0391493-852A
• Study Type: interventional
• Target: 42
• Locations: 1 country
• Sites: 1

Brief Summary

Study 1493-852A is a phase 1 study with the primary objective of determining safety and the highest tolerated dose of an experimental immune response modifier administered intravenously to patients with solid organ tumors not responsive to currently available treatments. The secondary objective of the study is to monitor the tumor response to this form of treatment.

Conditions

Neoplasms

Keywords

Solid Organ Tumors

Outcome Measures

Primary Outcomes (1)

• Safety and Pharmacokinetics

Secondary Outcomes (1)

• Tumor Response

Interventions

852A DRUG

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Have solid organ tumors refractory to currently available treatments.
• Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2
• Have a life expectancy of 4 months
• Have normal organ and bone marrow function

You may not qualify if:

• Have had biologic, hormonal, anti-neoplastic chemotherapy, or radiation therapy within 4 weeks prior to the 1st dose of the study drug or those who have not recovered from adverse events from agents administered more than 4 weeks earlier.
• Use of investigational agent in the 4 weeks prior to 1st dose of the study drug
• Use of immunosuppressive therapy in the 4 weeks prior to the 1st dose
• Have a history of, or clinical evidence of, myocardial ischemia, congestive heart failure, or myocardial arrhythmias requiring treatment within the past 6 months
• Have uncontrolled intercurrent or chronic illness, but not limited to, ongoing or active infection such as hepatitis B or C, immune dysfunction such as autoimmune disease, endocrine dysfunction such as hypo- or hyperthyroidism, psychiatric illness such as depression or suicidal tendency or social situations that would limit compliance with study requirements
• Have a history of disease requiring ongoing steroid treatment
• Have a history of seizure disorders uncontrolled on medication
• Have a history of clinically significant coagulation or bleeding disorders or abnormalities
• Are HIV positive. HIV positive subjects are excluded from the study because of possible interactions with the immunomodulatory effects of 852A and because of potential pharmacokinetic interactions associated with combination retroviral therapy.
• Are pregnant or lactating

Sponsors & Collaborators

• Masonic Cancer Center, University of Minnesota: lead
• Pfizer: collaborator

Study Sites (1)

University of Minnesota

Minneapolis, Minnesota, 55455, United States

Location

MeSH Terms

Conditions

Neoplasms

Study Officials

• Jeffrey Miller, MD

  Masonic Cancer Center, University of Minnesota

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: November 1, 2004
• First Posted: November 2, 2004
• Study Start: October 1, 2003
• Primary Completion: January 1, 2006
• Study Completion: January 1, 2006
• Last Updated: November 29, 2017

Record last verified: 2017-11

Locations

US (1)